Thomas Andrew Hardy

Title: Thomas Andrew Hardy: Innovator in Rapid-Acting Insulin Compositions

Introduction

Thomas Andrew Hardy is a notable inventor based in Carmel, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of rapid-acting insulin compositions. With a total of 4 patents to his name, Hardy's work has the potential to improve the lives of many individuals requiring insulin therapy.

Latest Patents

Hardy's latest patents focus on innovative pharmaceutical compositions of human insulin or insulin analogs. One of his key inventions is a rapid-acting insulin composition that includes citrate, treprostinil, and stabilizing agents. This formulation demonstrates faster pharmacokinetic and/or pharmacodynamic action compared to existing commercial insulin analog products, while also being stable for commercial use. Another significant patent involves a composition of human insulin or insulin analog that includes treprostinil, which also exhibits faster pharmacokinetic action than current commercial formulations.

Career Highlights

Thomas Andrew Hardy is currently employed at Eli Lilly and Company, a leading pharmaceutical firm known for its advancements in diabetes care and other therapeutic areas. His work at Eli Lilly has allowed him to focus on developing innovative solutions that address the needs of patients requiring insulin therapy.

Collaborations

Hardy has collaborated with several talented individuals in his field, including Michael Edward Christe and Michael Patrick Akers. These collaborations have likely contributed to the success of his innovative projects and patents.

Conclusion

In summary, Thomas Andrew Hardy is a distinguished inventor whose work in rapid-acting insulin compositions has the potential to transform diabetes management. His contributions to the pharmaceutical industry reflect a commitment to improving patient outcomes through innovation.